Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal men

No abstract is available for this paper.

• Publication year

  2004

• Venue

  BJU International

• Publication date

  2004-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/j.1464-410X.2003.04750.xPMID 15049991
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• [Is methyltestosterone no longer used therapeutically?].

  2008cited by this paper
• Statistical analysis of bioavailability studies: Parametric and nonparametric confidence intervals

  2004cited by this paper
• Endocrine Replacement Therapy in Clinical Practice

  2003cited by this paper
• Interrelationships among lipoprotein levels, sex hormones, anthropometric parameters, and age in hypogonadal men treated for 1 year with a permeation-enhanced testosterone transdermal system.

  2001cited by this paper
• Effects of transdermal testosterone gel on bone turnover markers and bone mineral density in hypogonadal men

  2001cited by this paper
• Effects of testosterone replacement in hypogonadal men.

  2000cited by this paper
• Pharmacokinetics of transdermal testosterone gel in hypogonadal men: application of gel at one site versus four sites: a General Clinical Research Center Study.

  2000cited by this paper
• Testosterone supplementation for erectile dysfunction: results of a meta-analysis.

  2000cited by this paper
• Androgen Replacement Therapy of Male Hypogonadism

  1999cited by this paper
• Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men.

  1999cited by this paper
• Androgen replacement in the treatment of Klinefelter's syndrome: efficacy and safety of a nonscrotal permeation-enhanced testosterone transdermal system.

  1998cited by this paper
• Testosterone and the aging male.

  1997cited by this paper
• Testosterone replacement increases fat-free mass and muscle size in hypogonadal men.

  1997cited by this paper
• Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.

  1997cited by this paper
• Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system.

  1997cited by this paper
• Long‐term efficacy and safety of a permeation‐enhanced testosterone transdermal system in hypogonadal men

  1997cited by this paper
• Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men--a clinical research center study.

  1996cited by this paper
• Testosterone replacement therapy improves mood in hypogonadal men--a clinical research center study.

  1996cited by this paper
• Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site- -a clinical research center study.

  1996cited by this paper
• Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system.

  1996cited by this paper
• Effects of testosterone replacement on muscle mass and muscle protein synthesis in hypogonadal men--a clinical research center study.

  1996cited by this paper
• Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism.

  1996cited by this paper
• Hypogonadism.

  1994cited by this paper
• Hypogonadotropic hypogonadism: gonadotropin therapy.

  1994cited by this paper
• A biodegradable testosterone microcapsule formulation provides uniform eugonadal levels of testosterone for 10-11 weeks in hypogonadal men.

  1992cited by this paper
• Pharmacokinetics and pharmacodynamics of testosterone pellets in man.

  1990cited by this paper
• High-density lipoprotein cholesterol is not decreased if an aromatizable androgen is administered.

  1990cited by this paper
• Testosterone replacement with transdermal therapeutic systems. Physiological serum testosterone and elevated dihydrotestosterone levels.

  1989cited by this paper
• Estradiol and testosterone metabolism and production in men with prostatic cancer.

  1989cited by this paper
• Quantitating genetic and nongenetic factors influencing androgen production and clearance rates in men.

  1988cited by this paper
• Transdermal testosterone therapy in the treatment of male hypogonadism.

  1988cited by this paper
• Production, clearance, and metabolism of testosterone in men with prostatic cancer

  1987cited by this paper
• A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability

  1987cited by this paper
• 高脂血症を伴わない糖尿病患者におけるHigh Density Lipoprotein Cholesterolと栄養素摂取の関係

  1982cited by this paper
• Treatment of male hypogonadism with testosterone enanthate.

  1980cited by this paper
• Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve

  1978cited by this paper
• Liver damage from long-term methyltestosterone.

  1977cited by this paper
• Male hypogonadism.

  1976cited by this paper
• Male hypogonadism.

  1955cited by this paper

• Testosterone Treatment Outcomes with Topical Gel versus Injectable Testosterone Undecamoate on Metabolic Syndrome and Sexual Function

  2025cites this paper
• Testosterone in men with hypogonadism and transgender males: a systematic review comparing three different preparations

  2022cites this paper
• Hormonal Replacement Therapy (HRT) and PDE 5 Inhibitors Response

  2016cites this paper
• Benefits and Harms of Testosterone Replacement Therapy in Hypogonadal Men: A Systematic Review and Network Meta-analysis

  2016cites this paper
• Late-onset hypogonadism or ADAM: treatment

  2014cites this paper
• guidelines in focus Late-onset hypogonadism or ADAM : treatment

  2014cites this paper
• Identification of hepatitis B virus genotypes in the state of São Paulo

  2014cites this paper
• Androgens and Endocrine Function in Aging Men: Effects on Sexual and General Health

  2012cites this paper
• Topical Testosterone Gel for the Treatment of Male Hypogonadism

  2012cites this paper
• Androgen Replacement Therapy

  2012cites this paper
• Testosterone Replacement Therapy for Men with Metabolic Syndrome

  2011cites this paper
• Testosterone replacement therapy in prostate cancer patients: is it safe?

  2010cites this paper
• A practical guide to male hypogonadism in the primary care setting

  2010cites this paper
• Advances in testosterone replacement therapy.

  2009cites this paper
• A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate.

  2008cites this paper
• Terapia sustitutiva con testosterona en el varón durante el envejecimiento

  2007cites this paper
• Testosterone therapy in the aging male

  2007cites this paper
• Transdermal testosterone gel increases serum testosterone levels in hypogonadal men in Taiwan with improvements in sexual function

  2007cites this paper
• Testosterone depot injection in male hypogonadism: a critical appraisal

  2007cites this paper
• 6.22 – Hormone Replacement

  2007cites this paper
• The role for intramuscular testosterone injection in the gel era

  2007cites this paper
• Hormonal Evaluation and Treatment

  2006cites this paper
• Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery

  2005cites this paper
• Male Hypogonadism

  2005cites this paper
• Delivery options for contraceptives.

  2005cites this paper
• Author index

  2004cites this paper